Novo Nordisk Plunges 2.45% as Morgan Stanley Sounds the Alarm on Patent Cliff

Summary
• Novo Nordisk (NVO) shares plummeted 2.45% intraday, closing at $42.9295 after Morgan Stanley downgraded the stock to 'Underweight'.

• The investment bank cited a looming 'large patent cliff' for Semaglutide, the active ingredient in Ozempic and Wegovy, which accounts for 75% of sales.

• Technical indicators flash bearish signals, with the stock trading below all major moving averages and the RSI sitting at 41.08.

• Retail sentiment on Stocktwits has turned neutral from bearish, with traders warning of a potential retest of the mid-30s support zone.
Morgan Stanley Downgrade Ignites Selling Pressure
The sharp decline in Novo Nordisk’s share price was directly triggered by a bearish reassessment from Morgan Stanley, which downgraded the pharmaceutical giant from 'Equal Weight' to 'Underweight'. The firm’s analysts, led by Thibault Boutherin, highlighted that the current valuation does not adequately reflect the subdued mid-term growth prospects or the severe implications of the Semaglutide patent cliff. With patent protection expiring in 2031 in Europe and 2032 in the U.S., Morgan Stanley warned that the loss of exclusivity poses a significant risk to the company’s terminal value. The bank maintained a $250 DKK price target, implying more than 10% downside from current levels, citing that oral obesity franchise revenue is unlikely to offset competitive and pricing headwinds.

Pharmaceutical Sector Weakness: LLY Leads Decline
The broader pharmaceutical sector mirrored the downturn, though Novo Nordisk’s decline was more pronounced than its primary competitor. Eli Lilly (LLY), the sector leader, also experienced a drop, with its intraday stock price changing by -0.50934996%. However, the divergence in sentiment suggests that investors are specifically punishing Novo Nordisk for its higher reliance on Semaglutide and the imminent patent expiry challenges, whereas Lilly’s Tirzepatide (Mounjaro/Zepbound) continues to show robust growth, with second-quarter sales surging 91% and 46% respectively. This competitive gap reinforces Morgan Stanley’s view that Novo Nordisk faces a 'large patent cliff' while its rivals continue to expand their market share.

Bearish Technical Setup and Strategic Put Options
The technical landscape for Novo Nordisk is decidedly bearish, with the stock trading well below its key moving averages and momentum indicators signaling continued weakness. Below is the technical breakdown:
• 200-day Moving Average: 46.29 (Below) – The stock is significantly underperforming its long-term trend, indicating a sustained downtrend.
• 50-day Moving Average (30D): 46.38 (Below) – Short-term resistance is firmly in place above current price levels.
• RSI: 41.08 (Neutral-Bearish) – The Relative Strength Index is approaching oversold territory but lacks bullish divergence, suggesting room for further decline.
• MACD: -0.588 (Below Signal) – The MACD line is below the signal line with a negative histogram, confirming downward momentum.

Key support is found at the 30D level of $47.05–$47.202, while resistance sits at the 200D level of $47.3398–$47.9136. Given the bearish sentiment and the patent cliff narrative, traders should look for opportunities to capitalize on further downside. The options chain offers compelling leverage for short-side strategies. We identify two top contracts based on high gamma, strong theta decay, and moderate delta for optimal risk-reward in a bearish scenario:

• NVO20260918P41.5 (Put Option)
- Strike: $41.5 | Expiration: 2026-09-18 | IV: 27.66% | Leverage: 214.50% | Delta: -0.199956 | Theta: -0.008070 | Gamma: 0.159287 | Turnover: 1847
- Delta: Sensitivity to price movement (-0.20 indicates moderate responsiveness to downside).
- Theta: Time decay rate (-0.008 shows steady erosion of premium for buyers).
- Gamma: Rate of change of delta (0.159 indicates high sensitivity to price swings).
This contract stands out for its high gamma, making it highly sensitive to intraday price drops. The leverage ratio of 214.50% offers substantial upside potential if the stock continues its slide, while the moderate delta ensures it is not overly expensive. It is ideal for traders expecting a sharp, short-term decline.

• NVO20260918C42 (Call Option)
- Strike: $42.0 | Expiration: 2026-09-18 | IV: 29.20% | Leverage: 33.52% | Delta: 0.698791 | Theta: -0.107212 | Gamma: 0.187586 | Turnover: 11668
- Delta: Sensitivity to price movement (0.70 indicates high responsiveness to upside moves).
- Theta: Time decay rate (-0.107 shows rapid erosion of premium, demanding quick action).
- Gamma: Rate of change of delta (0.188 indicates very high sensitivity to price swings).
Although this is a call option, the high turnover and gamma make it a popular choice for speculative bounces. However, in a bearish trend, this contract is risky. A better alternative for a bearish play with similar gamma is NVO20260918P42 (Put Option, Strike $42, Turnover 9597, Gamma 0.202, Delta -0.28). Let’s re-evaluate for a pure bearish setup with high gamma:

• NVO20260918P42 (Put Option)
- Strike: $42.0 | Expiration: 2026-09-18 | IV: 26.34% | Leverage: 143.00% | Delta: -0.282676 | Theta: -0.003210 | Gamma: 0.202053 | Turnover: 9597
- Delta: Sensitivity to price movement (-0.28 indicates good responsiveness to downside).
- Theta: Time decay rate (-0.003 shows slow erosion of premium, allowing more time).
- Gamma: Rate of change of delta (0.202 indicates very high sensitivity to price swings).
This contract offers the highest gamma in the chain for puts, making it extremely sensitive to price drops. The high turnover ensures liquidity, and the moderate delta provides a balance between cost and leverage. It is ideal for traders betting on a continued decline.

Payoff Calculation Primer: For a 5% downside scenario, the projected price (ST) would be approximately $40.78. For NVO20260918P42, the payoff would be max(0, 42.0 - 40.78) = $1.22 per share. This highlights the potential profit if the stock drops as anticipated.

If $42.72 breaks, NVO20260918P42 offers short-side potential with high gamma leverage.

Sell on Rallies: Watch for $42.72 Breakdown
The downward move in Novo Nordisk appears sustainable given the fundamental headwinds of patent expiry and the bearish downgrade from Morgan Stanley. Investors should remain cautious and consider selling on any minor rallies, as the stock is trading below all major moving averages. The key level to watch is $42.72; a break below this support could accelerate the decline towards the mid-30s. Meanwhile, sector leader Eli Lilly (LLY) also saw a -0.50934996% drop, reflecting broader sector weakness, but Novo Nordisk’s specific risks make it a prime candidate for short-term bearish trades. Watch for a sustained break below $42.72 or further negative analyst commentary to confirm the next leg down.